Conference Coverage

Hispanic diabetes patients receive less guideline-based care


 

FROM SGIM 2021

Focus on equitable early intervention

“There is plenty of evidence in the medical literature that Black and Hispanic individuals with diabetes, as well as other minorities, have higher risk of complications of diabetes such as retinopathy, nephropathy, as well as cardiovascular risk factors such as high blood pressure and cholesterol,” Dr. Marcondes said. “Yet, complications in the time that immediately follows the diagnosis of diabetes are likely to be low.”

To reduce the risk of complications in the future, “physicians and health providers need to focus on providing equitable, guideline-directed treatment for their minority patients recently diagnosed with diabetes,” Dr. Marcondes emphasized. “Intervening early in the disease course will hopefully lead to a decrease in the rate of complications for racial/ethnic minorities. Clinicians, especially primary care physicians and providers, need to be aware that they are often the first encounter of many patients with the health care system. Effective communication and unbiased language on the part of clinicians will lead to stronger patient-physician relationships that foster opportunity to discuss disease prevention.

“Additional research is needed to evaluate the attitudes and biases of primary care providers and access the impact of patient navigation resources when treating minority patients with diabetes,” he concluded.

Digging Deeper into Disparities
“In diabetes, there are known racial and ethnic disparities such that minorities receive suboptimal screening and treatment, and have worse outcomes,” said Scott J. Pilla, MD, of The Johns Hopkins University School of Medicine, Baltimore, in an interview.


“This study examines disparities in diabetes preventive measures in the U.S. using a national survey (NHIS) over the past decade. They took the important step of stratifying their analyses by health insurance and socioeconomic status which, in addition to race, may have a large impact,” said Dr. Pilla. However, “One critique of the poster is that it is unclear whether the researchers weighted their analyses to account for the nationally representative sampling of the NHIS survey,” he noted.
Dr. Pilla said the finding that Hispanic patients had fewer diabetes preventive measures lines up with previous research in this area.


“I was surprised that the disparities did not extend to black patients, who have been found to also receive suboptimal care compared to white patients in other studies,” he noted.


The message for clinical practice: “Minorities with diabetes are at a higher risk of adverse diabetes outcomes and may need extra support and resources to achieve their evidence-based diabetes prevention,” Dr. Pilla said.


“More research is needed to understand the root cause of racial and ethnic disparities in diabetes management to tease apart possible contributors including health insurance coverage, socioeconomic factors, cultural and community factors, and systemic racism. This will help inform targeted approaches to reducing disparities in diabetes care,” he emphasized.

The researchers had no relevant financial conflicts to disclose. Dr. Pilla had no financial conflicts to disclose.

Pages

Recommended Reading

Semaglutide for meaningful weight loss in obesity and diabetes?
Journal of Clinical Outcomes Management
Type 2 diabetes linked to increased risk for Parkinson’s
Journal of Clinical Outcomes Management
High obesity rates in Southern states magnify COVID threats
Journal of Clinical Outcomes Management
Diabetes prevention moves toward reality as studies published
Journal of Clinical Outcomes Management
Women with PCOS at increased risk for COVID-19
Journal of Clinical Outcomes Management
Use of complimentary and alternative medicine common in diabetes patients
Journal of Clinical Outcomes Management
FDA approves new ready-to-inject glucagon product
Journal of Clinical Outcomes Management
Six pregnancy complications flag later heart disease risk
Journal of Clinical Outcomes Management
Cardiovascular disease remains leading cause of type 2 diabetes mortality
Journal of Clinical Outcomes Management
FDA panel supports islet cell treatment for type 1 diabetes
Journal of Clinical Outcomes Management